Summary
23.04 -0.20(-0.84%)05/21/2024
Jasper Therapeutics Inc (JSPR)
Jasper Therapeutics Inc (JSPR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 7.03 | -7.33 | 1,849.45 | 1,421.62 | 698.58 | 523.82 | 0.00 | 12.60 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 24.02 | |
| Open | 22.34 | |
| High | 24.02 | |
| Low | 22.29 | |
| Volume | 19,035 | |
| Change | 1.58 | |
| Change % | 7.03 | |
| Avg Volume (20 Days) | 142,892 | |
| Volume/Avg Volume (20 Days) Ratio | 0.13 | |
| 52 Week Range | 0.40 - 14.76 | |
| Price vs 52 Week High | 62.72% | |
| Price vs 52 Week Low | 5,904.20% | |
| Range | 5.14 | |
| Gap Up/Down | -0.27 | |
Fundamentals | ||
| Market Capitalization (Mln) | 350 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 18.33 | |
| Book Value | 2.0100 | |
| Earnings Per Share | -0.8070 | |
| EPS Estimate Current Quarter | -0.2800 | |
| EPS Estimate Next Quarter | -0.2700 | |
| EPS Estimate Current Year | -2.7600 | |
| EPS Estimate Next Year | -1.1900 | |
| Diluted EPS (TTM) | -0.8070 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 37,853,200 | |
| Shares Float | 7,016,097 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 59.64 | |
| Institutions (%) | 38.44 | |
05/20 01:38 EST - https://www.defenseworld.net
Equities Analysts Offer Predictions for Jasper Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:JSPR)
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) – Equities research analysts at Capital One Financial upped their Q2 2024 earnings per share estimates for shares of Jasper Therapeutics in a research report issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of ($1.19) for the quarter, up from their prior estimate of ($1.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.35) per share. Capital One Financial also issued estimates for Jasper Therapeutics’ FY2024 earnings at ($4.64) EPS, FY2025 earnings at ($5.08) EPS, FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($2.74) EPS and FY2028 earnings at $2.23 EPS. A number of other equities research analysts also recently commented on JSPR. Oppenheimer reiterated an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Evercore ISI started coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 target price for the company. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 target price on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $64.29. Read Our Latest Stock Report on JSPR Jasper Therapeutics Price Performance JSPR stock opened at $23.02 on Monday. The firm has a market cap of $346.68 million, a PE ratio of -4.09 and a beta of 2.25. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a 50 day simple moving average of $25.12 and a 200 day simple moving average of $15.85. Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. Institutional Investors Weigh In On Jasper Therapeutics A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. grew its stake in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics in the 4th quarter worth about $197,000. Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $140,000. Finally, StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Hedge funds and other institutional investors own 79.85% of the company’s stock. Jasper Therapeutics Company Profile (Get Free Report) Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. Read More Five stocks we like better than Jasper Therapeutics What is the Euro STOXX 50 Index? MarketBeat Week in Review – 5/13 – 5/17 Low PE Growth Stocks: Unlocking Investment Opportunities Take-Two Interactive Software Offers 2nd Chance for Investors How to Effectively Use the MarketBeat Ratings Screener Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Equities Analysts Offer Predictions for Jasper Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:JSPR)
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) – Equities research analysts at Capital One Financial upped their Q2 2024 earnings per share estimates for shares of Jasper Therapeutics in a research report issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of ($1.19) for the quarter, up from their prior estimate of ($1.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.35) per share. Capital One Financial also issued estimates for Jasper Therapeutics’ FY2024 earnings at ($4.64) EPS, FY2025 earnings at ($5.08) EPS, FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($2.74) EPS and FY2028 earnings at $2.23 EPS. A number of other equities research analysts also recently commented on JSPR. Oppenheimer reiterated an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Evercore ISI started coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 target price for the company. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 target price on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $64.29. Read Our Latest Stock Report on JSPR Jasper Therapeutics Price Performance JSPR stock opened at $23.02 on Monday. The firm has a market cap of $346.68 million, a PE ratio of -4.09 and a beta of 2.25. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a 50 day simple moving average of $25.12 and a 200 day simple moving average of $15.85. Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. Institutional Investors Weigh In On Jasper Therapeutics A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. grew its stake in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics in the 4th quarter worth about $197,000. Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $140,000. Finally, StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Hedge funds and other institutional investors own 79.85% of the company’s stock. Jasper Therapeutics Company Profile (Get Free Report) Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. Read More Five stocks we like better than Jasper Therapeutics What is the Euro STOXX 50 Index? MarketBeat Week in Review – 5/13 – 5/17 Low PE Growth Stocks: Unlocking Investment Opportunities Take-Two Interactive Software Offers 2nd Chance for Investors How to Effectively Use the MarketBeat Ratings Screener Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/14 08:00 EST - globenewswire.com
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.
05/13 08:00 EST - globenewswire.com
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.
05/07 16:30 EST - globenewswire.com
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:
05/07 13:01 EST - zacks.com
Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know
Jasper Therapeutics (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know
Jasper Therapeutics (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
04/02 16:30 EST - globenewswire.com
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
03/22 09:51 EST - zacks.com
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
Jasper Therapeutics (JSPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
Jasper Therapeutics (JSPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
03/21 16:30 EST - globenewswire.com
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.
03/19 08:00 EST - globenewswire.com
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper's Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper's Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).
03/15 08:00 EST - globenewswire.com
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).
03/14 13:01 EST - zacks.com
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Does Jasper Therapeutics, Inc. (JSPR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Does Jasper Therapeutics, Inc. (JSPR) have what it takes to be a top stock pick for momentum investors? Let's find out.
03/06 09:51 EST - zacks.com
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going
Jasper Therapeutics, Inc. (JSPR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going
Jasper Therapeutics, Inc. (JSPR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
03/04 07:30 EST - globenewswire.com
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter and year ended December 31, 2023, and reported recent corporate developments.
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter and year ended December 31, 2023, and reported recent corporate developments.
02/26 16:30 EST - globenewswire.com
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the 43rd Annual TD Cowen Healthcare Conference at 10:30am EST on March 4, 2024.
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the 43rd Annual TD Cowen Healthcare Conference at 10:30am EST on March 4, 2024.
02/23 08:00 EST - globenewswire.com
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.
02/07 08:00 EST - globenewswire.com
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the Oppenheimer 34th Annual Healthcare Conference at 4:40pm EST on February 13, 2024. The conference is being held in a virtual format.
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the Oppenheimer 34th Annual Healthcare Conference at 4:40pm EST on February 13, 2024. The conference is being held in a virtual format.
02/06 08:59 EST - globenewswire.com
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten offering of 3,900,000 shares of its common stock. Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast-cell driven diseases such as CSU and Chronic Inducible Urticaria (CIndU), as well as general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions.
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten offering of 3,900,000 shares of its common stock. Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast-cell driven diseases such as CSU and Chronic Inducible Urticaria (CIndU), as well as general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions.
02/05 08:00 EST - globenewswire.com
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.
02/02 08:00 EST - globenewswire.com
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that, on January 31, 2024, three new employees were awarded grants of options to purchase an aggregate of 12,000 shares of voting common stock (the “Options”). Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper's board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to such employee's employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of each Option is $11.78. Each Option will vest over four years, with 25% of the total number of shares vesting on the one year anniversary of the date of commencement of such employee's employment with Jasper and 1/48th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee's continued service to Jasper on each vesting date.
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that, on January 31, 2024, three new employees were awarded grants of options to purchase an aggregate of 12,000 shares of voting common stock (the “Options”). Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper's board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to such employee's employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of each Option is $11.78. Each Option will vest over four years, with 25% of the total number of shares vesting on the one year anniversary of the date of commencement of such employee's employment with Jasper and 1/48th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee's continued service to Jasper on each vesting date.
01/24 13:16 EST - zacks.com
Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.